CAP-Certified Lab in Beijing Provides Extensive Testing and Pathology Expertise
Rochester, New York and York, England and Bethesda, Maryland, April 1, 2009-ACM Global Central Laboratory, the laboratory that continually defines the client-service standard with its inherently flexible approach, and Chindex International, Inc. (NASDAQ: CHDX), today announced a partnership to provide central lab services in China at United Family Hospitals, Beijing (“UFH”). UFH is a CAP-certified facility owned by Chindex International, Inc.
ACM Global Central Laboratory conducted a harmonization program in China, and chose to work with Chindex in order to ensure the same degree of global standards that clients enjoy from the Americas, Europe, India and Australasia. Offering on-the-ground central lab capabilities in China is a significant milestone in the organization’s history.
“Given the challenges of exporting whole blood from Mainland China coupled with the demand for conducting trials in China, we recognized the importance of establishing services locally,” said Elena Logan, Vice President, ACM Global Central Laboratory. “We also refuse to compromise on quality and working with Chindex helps us maintain our rigorous service standards in an exciting developing market. I’m honored to be able to work with the UFH team led by US trained pathologist, Dr. Sun Fei, who will oversee the clinical trial efforts at UFH.”
“As the only Western-founded hospital lab in Beijing, and the only JCI accredited hospital in China with CAP accreditation, we are well-poised to provide unparalleled central lab services. Working with a global leader like ACM acknowledges our unique competitive position as well as our dedication to high standards of care. We also look forward to providing additional diagnostic testing to the local community through this partnership,” said Roberta Lipson, CEO of Chindex.”
ACM’s global operations extend to more than 60 countries, including the Americas, Europe, including Eastern Europe and Russia, Australia, Asia, Israel, South Africa and India-with all tests conducted and managed from central lab facilities with seamless data management providing a single database. Combining comprehensive safety, efficacy and pathology testing from a single lab ensures clients receive consistent, analyzable test results with faster and cleaner reporting.
“China is an exciting and rapidly growing market for clinical trials and our central lab capabilities there represent an important development for the company” said Tracy Hendershott, Director, Global Operations “Partnering with a qualified lab in China gives us the ideal mix of global standardization combined with local expertise to deliver the best possible service to our clients.”
About ACM Global Central Lab
ACM Global Central Lab offers a flexible approach and a focus on precision to keep clinical research studies on schedule. ACM’s operations extend to more than 60 countries with all tests conducted and managed from central lab facilities with seamless data management providing a single database. The organization performs 13 million tests each year, featuring more than 1,500 individual tests spanning all medical disciplines, including pathology, microbiology, flow cytometry and pharmacogenomics. Combining comprehensive safety, efficacy and pathology testing from a single lab ensures clients receive consistent, analyzable test results with faster and cleaner reporting.
For more information, visit www.acmgloballab.com.
About Chindex International, Inc. and United Family Hospitals
Chindex is an American healthcare company that provides healthcare services and supplies medical capital equipment, instrumentation and products to the Chinese marketplace, including Hong Kong. Healthcare services are provided through the operations of its United Family Hospitals and Clinics, a network of private primary care hospitals and affiliated ambulatory clinics in China. The Company's hospital network currently operates in the Beijing, Shanghai, Guangzhou and Wuxi. The Company sells medical products manufactured by various major multinational companies, including Siemens AG and Intuitive Surgical, for which the Company is the exclusive distribution partner for the sale and servicing of color ultrasound systems and surgical robotic systems respectively. It also arranges financing packages for the supply of medical products to hospitals in China utilizing the export loan and loan guarantee programs of both the U.S. Export-Import Bank and the German KfW Development Bank. With twenty-seven years of experience, approximately 1,200 employees, and operations in China, Hong Kong, the United States and Germany, the Company's strategy is to expand its cross-cultural reach by providing leading edge healthcare technologies, quality products and services to Greater China's professional communities. Further company information may be found at the Company's websites, http://www.chindex.com and http://www.unitedfamilyhospitals.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.